Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM)-Reference-Cited by-同舟云学术

Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM)

Published:2020-06-15 Issue:4 Volume:106 Page:273-280
ISSN:0300-8916
Container-title:Tumori Journal
language:en
Short-container-title:Tumori

Author:

Tralongo Antonino C.¹^ORCID,Antonuzzo Andrea²,Pronzato Paolo³,Sbrana Andrea²^ORCID,Turrini Marianna⁴,Zoratto Federica⁵,Danova Marco⁶

Affiliation:

1. Medical Oncology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy

2. Medical Oncology 2, AOU Pisana, Pisa, Italy

3. Medical Oncology, AOU San Martino IRCCS IST Genova, Genova, Italy

4. Medical Oncology, Ospedale del Valdarno, Montevarchi, Italy

5. Medical Oncology, Ospedale S. Maria Goretti, Latina, Italy

6. Internal Medicine and Medical Oncology, ASST Pavia, Pavia, Italy

Abstract

Neutropenia is the most frequent side effect of commercially available myelosuppressive drugs and its most significant complication is febrile neutropenia. It is associated with increased hospital admissions and higher probability of death. Prophylaxis with the administration of granulocyte colony-stimulating factor can prevent neutropenia caused by anticancer drugs. The correct administration of these drugs and the management of febrile neutropenia are extremely important in the treatment of patients with cancer.

Publisher

SAGE Publications

Subject

Cancer Research,Oncology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/0300891620927093

Reference46 articles.

1. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy

2. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

3. Risk of mortality in patients with cancer who experience febrile neutropenia

4. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study

5. Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory and Nutritional Biomarkers in Patients With Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemotherapy and Radiation Therapy;Oncology Nursing Forum;2024-03-01

2. A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative;Supportive Care in Cancer;2023-10-13

3. Effects of pegylated recombinant human granulocyte colony-stimulating factor on lymphocytes and white blood cells of patients with malignant tumor;Open Life Sciences;2023-01-01

4. Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement;Supportive Care in Cancer;2022-11-05

5. A multinational, drug utilization study of lipegfilgrastim use in real-world setting in Europe;Supportive Care in Cancer;2022-08-31